Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HARRY E SARLES

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1861451395
CMS profile
311621
Location
ROCKWALL, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$46,210.39

151 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HARRY E SARLES

NPI 1861451395 · CMS profile ID 311621

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ROCKWALL, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861451395?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HARRY E SARLES, NPI 1861451395, CMS profile ID 311621. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861451395?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). HARRY E SARLES, NPI 1861451395, CMS profile ID 311621. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861451395?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
HARRY E SARLES, NPI 1861451395, CMS profile ID 311621, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1861451395?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

151 matching records · $46,210.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 151 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 151.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $5.4708/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137668640 CMS
ABBVIE INC. $15.1308/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106021342 CMS
ABBVIE INC. $8.6808/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106021340 CMS
ABBVIE INC. $21.7708/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106021338 CMS
GENZYME CORPORATION $24.0208/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139902990 CMS
Phathom Pharmaceuticals, Inc. $325.0007/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120766 CMS
ABBVIE INC. $23.7007/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106021336 CMS
Phathom Pharmaceuticals, Inc. $29.3007/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120756 CMS
Phathom Pharmaceuticals, Inc. $29.3007/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120758 CMS
Phathom Pharmaceuticals, Inc. $55.6107/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120760 CMS
Phathom Pharmaceuticals, Inc. $47.8707/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120762 CMS
Phathom Pharmaceuticals, Inc. $35.2307/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120764 CMS
Phathom Pharmaceuticals, Inc. $346.0907/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120750 CMS
Phathom Pharmaceuticals, Inc. $571.9507/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120752 CMS
Phathom Pharmaceuticals, Inc. $135.0007/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120754 CMS
ABBVIE INC. $16.8907/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106021334 CMS
Phathom Pharmaceuticals, Inc. $3,500.0007/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120748 CMS
Phathom Pharmaceuticals, Inc. $3,500.0007/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120746 CMS
ABBVIE INC. $14.2007/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106021332 CMS
Phathom Pharmaceuticals, Inc. $184.1007/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120738 CMS
Phathom Pharmaceuticals, Inc. $438.2107/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120740 CMS
Phathom Pharmaceuticals, Inc. $119.9007/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120742 CMS
Phathom Pharmaceuticals, Inc. $292.0007/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120744 CMS
ABBVIE INC. $24.4507/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106021330 CMS
GENZYME CORPORATION $19.4006/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139902970 CMS
Takeda Pharmaceuticals U.S.A., Inc. $5.4006/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137668638 CMS
ABBVIE INC. $15.1806/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106021328 CMS
ABBVIE INC. $8.8706/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106021326 CMS
ABBVIE INC. $13.3106/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106021324 CMS
Ardelyx, Inc. $17.6506/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146705947 CMS
Celgene Corporation $17.4906/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101110294 CMS
Janssen Scientific Affairs, LLC $140.4906/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078860525 CMS
Ferring Pharmaceuticals Inc. $18.7806/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137508150 CMS
SHIELD THERAPEUTICS INC $73.1006/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150134087 CMS
ABBVIE INC. $20.7206/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106021322 CMS
Phathom Pharmaceuticals, Inc. $16.4806/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120736 CMS
GENZYME CORPORATION $24.9905/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139902956 CMS
Phathom Pharmaceuticals, Inc. $80.4005/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120732 CMS
Phathom Pharmaceuticals, Inc. $46.9005/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120734 CMS
Ferring Pharmaceuticals Inc. $18.7705/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137508146 CMS
GENZYME CORPORATION $25.4505/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139902964 CMS
ABBVIE INC. $13.8105/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106021320 CMS
Takeda Pharmaceuticals U.S.A., Inc. $6.4705/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137668636 CMS
ABBVIE INC. $24.2105/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106021318 CMS
ABBVIE INC. $16.5005/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106021316 CMS
Phathom Pharmaceuticals, Inc. $2,500.0005/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120730 CMS
ABBVIE INC. $8.3705/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106021312 CMS
ABBVIE INC. $13.7805/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106021314 CMS
Phathom Pharmaceuticals, Inc. $2,500.0005/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120728 CMS
Phathom Pharmaceuticals, Inc. $52.5504/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151120726 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,296.43 69
PY2020 $2,943.10 40
PY2021 $2,207.37 110
PY2022 $2,059.70 93
PY2023 $6,304.29 137
PY2024 $46,210.39 151
PY2025 $6,594.60 92

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $134.26 2
PY2025 Principal investigator $225,854.87 68
PY2024 Principal investigator $291,590.16 32
PY2023 Recipient $20.09 1
PY2023 Principal investigator $278,289.44 38
PY2022 Recipient $845.67 1
PY2022 Principal investigator $298,537.94 65
PY2021 Recipient $11,777.72 6
PY2021 Principal investigator $506,702.67 85
PY2020 Recipient $171.90 1
PY2020 Principal investigator $1,100,186.30 202
PY2019 Recipient $4,459.85 15
PY2019 Principal investigator $1,314,813.06 219

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

70 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $2,626.40 12/26/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672814
Principal investigator 1 Boehringer Ingelheim International GmbH $903.00 12/19/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672816
Principal investigator 1 Boehringer Ingelheim International GmbH $903.00 12/19/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672818
Principal investigator 1 Boehringer Ingelheim International GmbH $4,183.20 12/19/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672820
Principal investigator 1 F. Hoffmann-La Roche AG $2,379.00 12/19/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663014
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 12/17/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672828
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 12/17/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672830
Principal investigator 1 ABBVIE INC. $9,039.80 12/16/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202530602
Principal investigator 1 ABBVIE INC. $1,932.15 12/04/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202527820
Principal investigator 1 Genentech, Inc. $2,743.00 11/25/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663460
Principal investigator 1 ABBVIE INC. $736.70 11/20/2025 Non-covered Recipient Entity
DIGESTIVE HEALTH ASSOCIATES OF TEXAS PA
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202525002
Principal investigator 1 Boehringer Ingelheim International GmbH $24,259.20 10/27/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672812
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 10/27/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672822
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 10/27/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672824
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 10/27/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672826
Recipient Eli Lilly and Company $64.26 10/20/2025 Covered Recipient Physician A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187876339
Principal investigator 1 ABBVIE INC. $3,100.00 10/09/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202514755
Principal investigator 1 Genentech, Inc. $2,540.00 10/09/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663378
Recipient Eli Lilly and Company $70.00 09/30/2025 Covered Recipient Physician A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 No dispute reported 06/30/2026 1187872413
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 09/24/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672806
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 09/24/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672808
Principal investigator 1 Boehringer Ingelheim International GmbH $2.00 09/24/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672810
Principal investigator 1 F. Hoffmann-La Roche AG $7,218.00 09/23/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211662933
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,276.00 09/18/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants, PLLC
A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD) No dispute reported 06/30/2026 1244044792
Principal investigator 1 ABBVIE INC. $3,600.00 09/10/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202510510
Principal investigator 1 AstraZeneca UK Limited $3,900.00 09/10/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLANO
A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients with Moderate to Severe Crohns Disease AMALTHEA No dispute reported 06/30/2026 1185539061
Principal investigator 1 ABBVIE INC. $5,100.00 09/04/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202509656
Principal investigator 1 ABBVIE INC. $3,767.40 09/04/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202509658
Principal investigator 1 ABBVIE INC. $3,600.00 08/26/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202505869
Principal investigator 1 ABBVIE INC. $3,600.00 08/26/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202505871
Principal investigator 1 ABBVIE INC. $7,058.80 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202503545
Principal investigator 1 ABBVIE INC. $1,526.20 08/05/2025 Non-covered Recipient Entity
DIGESTIVE HEALTH ASSOCIATES OF TEXAS PA
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202502170
Principal investigator 1 F. Hoffmann-La Roche AG $6,635.00 07/31/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211662962
Principal investigator 1 ABBVIE INC. $665.00 07/11/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1202498110
Principal investigator 1 ABBVIE INC. $6,186.25 07/02/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202496379
Principal investigator 1 ABBVIE INC. $321.30 07/02/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202496503
Principal investigator 1 ABBVIE INC. $4,971.40 07/02/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202496505
Principal investigator 1 Genentech, Inc. $7,695.00 06/19/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663083
Principal investigator 1 ABBVIE INC. $3,599.40 06/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202491171
Principal investigator 1 ABBVIE INC. $1,181.70 06/12/2025 Non-covered Recipient Entity
DIGESTIVE HEALTH ASSOCIATES OF TEXAS PA
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202491175
Principal investigator 1 ABBVIE INC. $6,187.50 06/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202491177
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 05/27/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672796
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 05/27/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672798
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 05/27/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672800
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 05/27/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672802
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 05/27/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672804
Principal investigator 1 ABBVIE INC. $3,599.40 05/15/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202485181
Principal investigator 1 ABBVIE INC. $3,767.40 04/03/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202473376
Principal investigator 1 ABBVIE INC. $428.00 04/03/2025 Non-covered Recipient Entity
DIGESTIVE HEALTH ASSOCIATES OF TEXAS PA
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202473379
Principal investigator 1 Boehringer Ingelheim International GmbH $33.71 03/24/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672780
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 03/24/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672782
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 03/24/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672784
Principal investigator 1 Boehringer Ingelheim International GmbH $259.00 03/24/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672786
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 03/24/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672788
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 03/24/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672790
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 03/24/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672792
Principal investigator 1 Boehringer Ingelheim International GmbH $21.43 03/24/2025 Non-covered Recipient Entity
Digestive Health Associates Of Texas Garland-N Pgb Highway
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220672794
Principal investigator 1 ABBVIE INC. $6,925.80 03/07/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202459170
Principal investigator 1 ABBVIE INC. $3,141.00 03/06/2025 Non-covered Recipient Entity
DIGESTIVE HEALTH ASSOCIATES OF TEXAS PA
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202456395
Principal investigator 1 Genentech, Inc. $4,940.00 02/18/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663109
Principal investigator 1 Genentech, Inc. $16,500.00 02/18/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663213
Principal investigator 1 ABBVIE INC. $941.85 02/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202446757
Principal investigator 1 ABBVIE INC. $941.85 01/17/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202439856
Principal investigator 1 ABBVIE INC. $2,500.00 01/17/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE
M21-446 - Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1202439859
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $20,671.00 01/15/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants Southlake
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice No dispute reported 06/30/2026 1235993301
Principal investigator 1 ABBVIE INC. $2,310.00 01/14/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202438516
Principal investigator 1 Celgene Corporation $12,700.00 01/13/2025 Non-covered Recipient Entity
GI Alliance Department Of Clinical Research And Education
A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1222307037
Principal investigator 1 ABBVIE INC. $2,310.00 01/09/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202437772
Principal investigator 1 ABBVIE INC. $1,481.25 01/02/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202433438
Principal investigator 1 ABBVIE INC. $1,306.50 01/02/2025 Non-covered Recipient Entity
DIGESTIVE HEALTH ASSOCIATES OF TEXAS PA
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202435890

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 1
PY2024 Value of interest $13,618.93 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $13,618.93 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $855.42 1
PY2021 Amount invested $725.07 1
PY2021 Value of interest $906.58 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

4 records · PY2021–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 GastroGPO, LLC $0.00 $13,618.93 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124820230
PY2023 GastroGPO, LLC $0.00 $13,618.93 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1050730605
PY2022 GastroGPO, LLC $0.00 $855.42 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 955001111
PY2021 GastroGPO, LLC $725.07 $906.58 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 854913981